Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major

Eastern Mediterranean Health Journal

Volumn 15, Issue 4, 2009, Pages 785-791

  Saffar, M J ^a   Saffar, H ^a   Khalilian, A R ^a   Naqshvar, F ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; PEGFERON B3; PEGINTERFERON ALPHA; RIBACIP 200; RIBAVIRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HEPATITIS C; HUMAN; LEUKOPENIA; MALAISE; MALE; MONOTHERAPY; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 73149087432     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2009.15.4.785     Document Type: Article

References (21)

1. Alter HJ. Epidemiology of hepatitis C. Hepatology, 1997, 26:62S-5S.
2. Wonke B et al. Antibody to hepatitis C virus in multiply transfused patients with thalassemia major. Journal of pathology, 1990, 43:638-40.
3. Lai ME et al. Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. Journal of pediatric gastroenterology and nutrition, 1993, 16:458-64.
4. Resti M et al. Hepatitis C virus antibodies in a long-term follow-up of beta-thalassemic children with acute and chronic non-A, non-B hepatitis. European journal of pediatrics, 1993, 152:538-9.
5. Angelucci E. Antibodies to hepatitis C virus in thalassemia. Hematologica, 1994, 79:353-5.
6. Zurlo MG et al. Survival and causes of death in thalassaemia major. Lancet, 1989, 2:27-30.
7. Teo M, Hayes P. Management of hepatitis C. British medical bulletin, 2004, 70:51-69.
8. Poynard T et al. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 1998, 352:1426-32.
9. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Seminars in liver disease, 1999, 19(Suppl.):57-65.
10. Camma C et al. Retreatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: a meta-analysis of individual patients' data. Gut, 2002, 51:864-9.
11. Van VlierbergheH et al. Factors influencing ribavirin induced hemolysis. Journal of hepatology, 2001, 34:911-6.
12. Saab S. Martin P. Hemolytic anemia and the treatment of chronic hepatitis C. Journal of clinical gastroenterology, 1999, 28:289-90.
13. Takaki S et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. Journal of gastroenterology, 2004, 39:668-73.
14. Sulkowaski MS et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of viral hepatitis, 2004, 11:243-50.
15. Kosarian M et al. Clinical trial of the effect of α-interferon on active chronic hepatitis C infection in β-thalassemia major. Nameh daneshgah (Journal of Mazandaran University of Medical Sciences), 1999, 19(24):13-8 [in Farsi].
16. Di Marco V et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood, 1997, 90(6):2207-12.
17. Donohue SM et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. British journal of haematology, 1993, 83(3):491-7.
18. Telfer PT et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. British journal of haematology, 1997, 98(4):850-5.
19. Li CK et al. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. British journal of haematology, 2002, 117(3):755-8.
20. Inati A et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. British journal of haematology, 2005, 130(4):644-6.
21. Aldouri MA et al. Iron state and hepatic disease in patients with thalassemia major treated with long-term subcutaneous desferrioxamine. Journal of clinical pathology, 1987, 40:1353-9.